What is Waterborne?
Established in 1991, Waterborne Inc. is a prominent provider of Giardia and Cryptosporidium products essential for water testing and research. The company specializes in advanced fluorescent and monoclonal antibody products for detecting infectious waterborne protozoa, alongside purified parasite forms and immunofluorescence-related materials. Waterborne Inc. serves a diverse global clientele, including private, national, and municipal drinking water laboratories, as well as research institutions and development firms. Their commitment to delivering high-quality products at competitive prices, backed by responsive customer service and technical support, solidifies their market standing.
How much funding has Waterborne raised?
Waterborne has raised a total of $76K across 1 funding round:
Debt
$76K
Debt (2021): $76K with participation from PPP
What's next for Waterborne?
The recent influx of expansion capital at a significant Series B/C stage suggests Waterborne Inc. is poised for accelerated growth and market penetration. This strategic investment will likely fuel advancements in product development, enhance operational capacity, and potentially expand its reach into new geographical markets or application areas within water quality analysis. The company's focus on critical pathogen detection indicates a continued emphasis on public health and environmental safety.
See full Waterborne company page
